Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 6:37 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 1,017 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Systemic Infection Clear all
Completed Phase 4 Interventional

Vasopressin for Septic Shock Pragmatic Trial

NCT06217562
View directory record Official record
Conditions
Septic Shock
Interventions
Vasopressin, Recommendation to use a lower initiation threshold for vasopressin, Recommendation to use a higher initiation threshold for vasopressin
Drug · Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
3,959 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Burley, Idaho • American Fork, Utah • Cedar City, Utah + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Nov 2, 2026, 6:37 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects

NCT00940017
View directory record Official record
Conditions
Aspergillosis, Candidemia
Interventions
anidulafungin and voriconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 9, 2010 · Synced Nov 2, 2026, 6:37 PM EST
Completed Not applicable Interventional Results available

Parafilm to Prevent CLABSI in Pediatric Patients Undergoing HCT

NCT02575079
View directory record Official record
Conditions
Central Line Associated Bloodstream Infections (CLABSI), Bone Marrow Transplant
Interventions
Parafilm
Device
Lead sponsor
Emory University
Other
Eligibility
Up to 21 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Nov 2, 2026, 6:37 PM EST
Completed No phase listed Observational

Effect of CRRT Duration on Solute Removal

NCT04458571
View directory record Official record
Conditions
AKI, Sepsis
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Nov 2, 2026, 6:37 PM EST
Completed Phase 1 Interventional

Alirocumab in Patients with Sepsis

NCT05469347
View directory record Official record
Conditions
Sepsis
Interventions
Alirocumab, Placebo
Drug
Lead sponsor
Jonathan Sevransky
Other
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Nov 2, 2026, 6:37 PM EST
Recruiting Phase 2 Interventional

Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

NCT05892614
View directory record Official record
Conditions
Interstitial Lung Disease
Interventions
efzofitimod 450 mg, efzofitimod 270 mg, Placebo
Drug
Lead sponsor
aTyr Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Nov 2, 2026, 6:37 PM EST
Terminated Phase 4 Interventional Results available

Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation

NCT04673175
View directory record Official record
Conditions
Pneumonia, Hematologic Malignancy, Pseudomonas Aeruginosa Infection, Bacteremia, Hematopoietic Stem Cell Transplant (HSCT)
Interventions
Ceftolozane / Tazobactam Injection
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Nov 2, 2026, 6:37 PM EST
Completed No phase listed Observational

Improved Patient Safety Through Continuous Bi-channel RR and SpO2 Monitoring With Masimo Patient SafetyNet

NCT03043911
View directory record Official record
Conditions
Signs and Symptoms, Respiratory
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Nov 2, 2026, 6:37 PM EST
Completed Phase 1 Interventional

Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug

NCT00608335
View directory record Official record
Conditions
Oropharyngeal Candidiasis, Candidemia, Invasive Candidiasis, Esophageal Candidiasis
Interventions
Micafungin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
2 Years to 16 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
7
States / cities
Los Angeles, California • Orange, California • Kansas City, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Nov 2, 2026, 6:37 PM EST
Terminated Phase 2 Interventional

An Open-Label, Study to Treat Patients With Renal Allograft and Polyoma BK Viruria

NCT01620268
View directory record Official record
Conditions
Viruria, Viremia
Interventions
Leflunomide and orotic acid
Drug
Lead sponsor
Changzheng-Cinkate
Industry
Eligibility
Up to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
9
States / cities
Birmingham, Alabama • Tampa, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Nov 2, 2026, 6:37 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Novel Mechanisms and Approaches to Treat Neonatal Sepsis

NCT02554630
View directory record Official record
Conditions
Complication of Prematurity, Immunologic Deficiency Syndromes
Interventions
Adjuvant, Blood Collection
Other
Lead sponsor
University of Florida
Other
Eligibility
Up to 55 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Nov 2, 2026, 6:37 PM EST
Not listed No phase listed Observational

Electronic Application of a Severe Sepsis Screening Tool and Management Bundle

NCT01724463
View directory record Official record
Conditions
Systemic Inflammatory Response Syndrome (SIRS), Sepsis, Severe Sepsis, Septic Shock
Interventions
Severe Sepsis Management Bundle
Other
Lead sponsor
University of Tennessee
Other
Eligibility
1 Month to 18 Years
Enrollment
30,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Nov 2, 2026, 6:37 PM EST
Not listed No phase listed Observational

Symphony IL-6 Cutoff Validation Study for Patients at Risk of Severe Sepsis

NCT05048927
View directory record Official record
Conditions
Severe Sepsis
Interventions
Not listed
Lead sponsor
Bluejay Diagnostics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Acton, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Nov 2, 2026, 6:37 PM EST
Completed Not applicable Interventional Results available

Safe Critical Care: Testing Improvement Strategies

NCT00975923
View directory record Official record
Conditions
Central Line-associated Bloodstream Infection (CLABSI), Ventilator Associated Pneumonia
Interventions
Collaborative Group, Tool Kit
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
1 Year and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Nov 2, 2026, 6:37 PM EST
Completed No phase listed Observational

Procalcitonin at Zero and 24 Hours as a Prognostic Factor in Patients With Pneumonia

NCT03711227
View directory record Official record
Conditions
Pneumonia
Interventions
Procalcitonin lab test
Diagnostic Test
Lead sponsor
Corewell Health South
Other
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Saint Joseph, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Nov 2, 2026, 6:37 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Hypoxia Inducible Factor 1 Alpha as a Novel Biomarker in Septic Shock

NCT02163473
View directory record Official record
Conditions
Sepsis
Interventions
Septic patients, Healthy Control
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2016 · Synced Nov 2, 2026, 6:37 PM EST
Completed Not applicable Interventional

Study of the Relationship Between Feeding and Late Onset Sepsis and/or Necrotizing Enterocolitis in Low Birth Weight Infants

NCT00005888
View directory record Official record
Conditions
Necrotizing Enterocolitis, Sepsis
Interventions
Fortified Pasteurized Donor Human Milk supplement, Preterm Formula supplement
Behavioral
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years to 96 Hours
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 2, 2026, 6:37 PM EST
Completed Phase 2 Interventional Results available

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma

NCT00392834
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, pegfilgrastim, rituximab, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, liposomal cytarabine, methotrexate, therapeutic hydrocortisone, vincristine sulfate
Biological · Drug
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
13
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Nov 2, 2026, 6:37 PM EST
Completed Phase 2 Interventional

Daptomycin in the Treatment of Catheter-Related Staphylococcus Aureus

NCT00507247
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
Daptomycin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Nov 2, 2026, 6:37 PM EST
Not listed Phase 3 Interventional

Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19

NCT04433949
View directory record Official record
Conditions
Pneumonia, Severe Acute Respiratory Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Best Practice, Low Dose Radiation Therapy
Other · Radiation
Lead sponsor
Emory University
Other
Eligibility
50 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Nov 2, 2026, 6:37 PM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock

NCT00604214
View directory record Official record
Conditions
Sepsis
Interventions
Drotrecogin alfa (activated), Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
23
States / cities
Birmingham, Alabama • Loma Linda, California • Long Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Nov 2, 2026, 6:37 PM EST
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis

NCT00646399
View directory record Official record
Conditions
Staphylococcal Sepsis
Interventions
Placebo, Pagibaximab 50 mg/mL
Drug
Lead sponsor
Biosynexus Incorporated
Industry
Eligibility
Up to 48 Hours
Enrollment
1,579 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Gaithersburg, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 24, 2011 · Synced Nov 2, 2026, 6:37 PM EST
Completed Phase 2 Interventional Results available

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

NCT04492514
View directory record Official record
Conditions
COVID 19, SARS-CoV 2, Pneumonia
Interventions
Mavrilimumab, Placebo
Drug
Lead sponsor
Kristin Hudock
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Nov 2, 2026, 6:37 PM EST
Completed Phase 4 Interventional Results available

Post Operative Sore Throat and Dexamethasone

NCT01052038
View directory record Official record
Conditions
Sore Throat, Pain
Interventions
Placebo administration, Dexamethasone 0.05mg/kr administration, Dexamethasone 0.1mg/kg
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 2, 2012 · Synced Nov 2, 2026, 6:37 PM EST